Nanocomposite formulation system of lipid-regulating drugs based on layered double hydroxide: synthesis, characterization and drug release properties.
OBJECTIVE
To design a nanocomposite formulation system of lipid-regulating drugs with versatile approaches using layered double hydroxide (LDH) material.


METHODS
The co-precipitation technique has been used to prepare the selected drugs [bezafibrate (BZF) and clofibric acid (CF)]-LDH nanocomposites. The nanocomposite materials (BZF-LDH and CF-LDH) were characterized by X-ray powder diffraction, infrared spectroscopy, thermogravimetric analysis, and scanning electron microscopy. The in vitro study was investigated in simulated gastrointestinal solutions at 36.8°C.


RESULTS
X-ray measurement and spectroscopic analysis indicated the formation of fully monophase drug-nanocomposites. The nanocomposites' gallery heights were calculated to be 23.5 and 16.3 Å for BZF and CF, respectively. The new gallery heights indicated that BZF and CF drugs have been stacked into LDH as a monolayer with a staggered inter-digitated arrangement. The size of the nanocomposites described by SEM microscopy was ∼ 0.1 μm. The nanocomposite formulation has improved the drugs properties (thermal stability, dissolution, and controlled release) beside the achievement of drug target delivery.


CONCLUSIONS
Nanocomposites composed of lipid-regulating drugs (BZF and CF) with LDH were successfully synthesized as a new formulation system of this drug category. The LDH nanocomposite formulation system has improved the drugs release properties.
Institute of Technology and Science, The University of Tokushima, Tokushima, 770-8506, Japan. mrberber@sy34.chem.tokushima-u.ac.jp
Mohamed R
MR
Berber
Inas H
IH
Hafez
Keiji
K
Minagawa
Takeshi
T
Mori
Masami
M
Tanaka
D000960:Hypolipidemic Agents / Q000737:chemistry*; D008855:Microscopy, Electron, Scanning; D053761:Nanocomposites; D013055:Spectrophotometry, Infrared; D013818:Thermogravimetry; D014961:X-Ray Diffraction
D000960:Hypolipidemic Agents